Enterprise Value
1.902B
Cash
45.95M
Avg Qtr Burn
-83.85M
Short % of Float
44.57%
Insider Ownership
72.58%
Institutional Own.
10.66%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Anktiva (N-803) Details Bladder cancer, Cancer | PDUFA Approval decision | |
PD-L1 t-haNK Details Pancreatic cancer, Cancer | Phase 2/3 Update | |
hAd5-COVID-19 Details Vaccine, COVID-19 | Failed Discontinued | |
N-803 (Anktiva), haNK and Avelumab Details Metastatic merkel cell carcinoma, Insomnia, Mood disorders, Liver transplant, Cancer | Failed Discontinued | |
Anktiva (N-803) + KEYTRUDA Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Failed Discontinued |